Friday, January 25, 2019

• Welcome and Keynote Address

Saturday, January 26, 2019

• EGFR and ALK in the first-, second-, and third-line
• Overcoming mechanisms of resistance for targeted therapy
• New oncogenic drivers including ROS1 and BRAF
• Future targets, such as RET, MET, and HER2
• Practical applications of immunotherapy
• I/O as a single-agent or in combination
• Differences in approaching squamous and nonsquamous NSCLC
• Fighting immunotherapy resistance pathways
• Current topics in lung cancer surgery
• Best practices for radiation therapy in lung cancer
• I/O and targeted therapies in the neoadjuvant setting

Sunday, January 27, 2019

• Methods to integrate palliative care
• The future of lung cancer therapy
• Immunotherapy beyond PD-(L)1 and CTLA-4
• What are the new standards for small cell lung cancer?
• Emerging approaches for mesothelioma
• Role of I/O for unresectable disease
• Managing immune-related adverse events
• Determining biomarkers for checkpoint inhibitors: PD-L1 vs. TMB
• What are the new standards of care?